1. Home
  2. PGEN vs REAL Comparison

PGEN vs REAL Comparison

Compare PGEN & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.10

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo The RealReal Inc.

REAL

The RealReal Inc.

HOLD

Current Price

$10.15

Market Cap

1.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGEN
REAL
Founded
1998
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Specialty Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.9B
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
PGEN
REAL
Price
$4.10
$10.15
Analyst Decision
Buy
Buy
Analyst Count
5
8
Target Price
$8.33
$17.00
AVG Volume (30 Days)
5.2M
3.0M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.55
EPS
N/A
N/A
Revenue
$230,981,000.00
$692,845,000.00
Revenue This Year
$1,115.92
$14.30
Revenue Next Year
$81.04
$10.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.38
52 Week Low
$1.23
$4.71
52 Week High
$5.47
$17.39

Technical Indicators

Market Signals
Indicator
PGEN
REAL
Relative Strength Index (RSI) 57.90 51.93
Support Level $4.02 $9.61
Resistance Level $4.44 $11.48
Average True Range (ATR) 0.32 0.52
MACD 0.12 0.23
Stochastic Oscillator 83.08 84.90

Price Performance

Historical Comparison
PGEN
REAL

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

About REAL The RealReal Inc.

The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.

Share on Social Networks: